Please provide your email address to receive an email when new articles are posted on . Although treating alcohol use disorders with baclofen was linked to higher rates of abstinence than placebo, it ...

December 7, 2007 -- Results of a randomized trial show alcohol-dependent patients with liver cirrhosis were able to attain alcohol abstinence at a higher rate with baclofen, an anticraving agent with ...

The drug baclofen has received high visibility as a possible breakthrough treatment for alcohol dependence. Now a new randomized controlled trial found no evidence for the usefulness of high-dose ...

Another study of high-dose baclofen (multiple brands), widely used in France to treat alcohol dependence, found that the drug does not appear to bolster abstinence rates, suggesting its use should be ...

Data showed a significant effect on abstinence rates with the use of baclofen (odds ratio [OR] 2.67, 95% CI: 1.03, 6.93) but no other significant effects on treatment efficacy (heavy drinking days SMD ...

Baclofen can be a miracle drug for some people who are addicted to alcohol. Baclofen is a medication that can be used for the treatment of addiction to alcohol. It is a medication that has actually ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Back to Healio SAN DIEGO — Baclofen failed to best ...

The drug baclofen is effective at promoting alcohol abstinence in alcohol-dependent patients with liver cirrhosis, and could have an important role in treatment of these individuals. These are the ...

French doctor writes about his belief that a drug could cure alcoholism. Jan. 14, 2009 — -- Dr. Olivier Ameisen, a French cardiologist, made international headlines with his claim that a muscle ...

Baclofen, a GABA B receptor agonist traditionally used as a muscle relaxant, has emerged as a promising pharmacological option in the management of Alcohol Use Disorder (AUD). By modulating inhibitory ...

This was a randomized, between-subject, double-blind, placebo-controlled, human laboratory study conducted at the National Institutes of Health (NIH) Clinical Center in Bethesda, MD, from January 2013 ...